{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T03:33:56Z","timestamp":1764646436667},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00115-023-01463-x","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T14:07:34Z","timestamp":1680185254000},"page":"501-509","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Myasthenie bei Erwachsenen, Kindern und Jugendlichen\u00a0\u2013 was ist neu?","Myasthenia in adults, children, and adolescents: what\u2019s new?"],"prefix":"10.1007","volume":"94","author":[{"given":"Frauke","family":"Stascheit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adela","family":"Della Marina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"issue":"4","key":"1463_CR1","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","volume":"98","author":"RJ Nowak","year":"2021","unstructured":"Nowak\u00a0RJ, Coffey\u00a0CS, Goldstein\u00a0JM, Dimachkie\u00a0MM, Benatar\u00a0M, Kissel\u00a0JT, Wolfe\u00a0GI, Burns\u00a0TM, Freimer\u00a0ML, Nations\u00a0S, Granit\u00a0V, Smith\u00a0AG, Richman\u00a0DP, Ciafaloni\u00a0E, Al-Lozi\u00a0MT, Sams\u00a0LA, Quan\u00a0D, Ubogu\u00a0E, Pearson\u00a0B, Sharma\u00a0A, Yankey\u00a0JW, Uribe\u00a0L, Shy\u00a0M, Amato\u00a0AA, Conwit\u00a0R, O\u2019Connor\u00a0KC, Hafler\u00a0DA, Cudkowicz\u00a0ME, Barohn\u00a0RJ; NeuroNEXT NN103 BeatMG Study Team (2021) Phase\u00a02 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study. Neurology 98(4):e376\u2013e389. https:\/\/doi.org\/10.1212\/WNL.0000000000013121","journal-title":"Neurology"},{"issue":"11","key":"1463_CR2","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl\u00a0F, Eriksson-Dufva\u00a0A, Budzianowska\u00a0A, Feresiadou\u00a0A, Hansson\u00a0W, Hietala\u00a0MA, H\u00e5kansson\u00a0I, Johansson\u00a0R, Jons\u00a0D, Kmezic\u00a0I, Lindberg\u00a0C, Lindh\u00a0J, Lundin\u00a0F, Nygren\u00a0I, Punga\u00a0AR, Press\u00a0R, Samuelsson\u00a0K, Sundstr\u00f6m\u00a0P, Wickberg\u00a0O, Brauner\u00a0S, Frisell\u00a0T (2022) Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol 79(11):1105\u20131112. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2887","journal-title":"JAMA Neurol"},{"key":"1463_CR3","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","volume":"76","author":"D Barth","year":"2011","unstructured":"Barth\u00a0D, Nabavi\u00a0NM, Ng\u00a0E et\u00a0al (2011) Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 76:2017\u20132023","journal-title":"Neurology"},{"key":"1463_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.2174\/1574886313666180508122332","volume":"13","author":"D Benfaremo","year":"2018","unstructured":"Benfaremo\u00a0D, Manfredi\u00a0L, Luchetti\u00a0MM et\u00a0al (2018) Musculoskeletal and rheumatic diseases induced by immune checkpoint inhibitors: a review of the literature. CDS 13:150\u2013164","journal-title":"CDS"},{"key":"1463_CR5","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","volume":"77","author":"S Brauner","year":"2020","unstructured":"Brauner\u00a0S, Eriksson-Dufva\u00a0A, Hietala\u00a0MA et al (2020) Comparison between Rituximab treatment for new-onset generalized myasthenia Gravis and refractory generalized myasthenia gravis. JAMA Neurol 77:974\u2013981","journal-title":"JAMA Neurol"},{"key":"1463_CR6","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/mus.21195","volume":"39","author":"LM Chiang","year":"2009","unstructured":"Chiang\u00a0LM, Darras\u00a0BT, Kang\u00a0PB (2009) Juvenile myasthenia gravis. Muscle Nerve 39:423\u2013431","journal-title":"Muscle Nerve"},{"key":"1463_CR7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S1474-4422(14)70201-7","volume":"14","author":"AG Engel","year":"2015","unstructured":"Engel\u00a0AG, Shen\u00a0XM, Selcen\u00a0D et\u00a0al (2015) Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol 14:420\u2013434","journal-title":"Lancet Neurol"},{"key":"1463_CR8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/mus.25085","volume":"54","author":"N Garg","year":"2016","unstructured":"Garg\u00a0N, Yiannikas\u00a0C, Hardy\u00a0TA et\u00a0al (2016) Late presentations of congenital myasthenic syndromes: how many do we miss? Muscle Nerve 54:721\u2013727","journal-title":"Muscle Nerve"},{"key":"1463_CR9","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus\u00a0NE, Verschuuren\u00a0JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036","journal-title":"Lancet Neurol"},{"key":"1463_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02147-5","author":"S Hoffmann","year":"2020","unstructured":"Hoffmann\u00a0S, Harms\u00a0L, Schuelke\u00a0M et\u00a0al (2020) Complement deposition at the neuromuscular junction in seronegative myasthenia gravis. Acta Neuropathol. https:\/\/doi.org\/10.1007\/s00401-020-02147-5","journal-title":"Acta Neuropathol"},{"key":"1463_CR11","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr.","year":"2021","unstructured":"Howard\u00a0JF Jr., Bril\u00a0V, Vu\u00a0T et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a\u00a0multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20:526\u2013536","journal-title":"Lancet Neurol"},{"key":"1463_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.5125","author":"JF Howard Jr.","year":"2020","unstructured":"Howard\u00a0JF Jr., Nowak\u00a0RJ, Wolfe\u00a0GI et al (2020) Clinical effects of the self-administered subcutaneous complement inhibitor Zilucoplan in patients with moderate to severe generalized myasthenia Gravis: results of a\u00a0phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2019.5125","journal-title":"JAMA Neurol"},{"key":"1463_CR13","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr.","year":"2017","unstructured":"Howard\u00a0JF Jr., Utsugisawa\u00a0K, Benatar\u00a0M et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a\u00a0phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976\u2013986","journal-title":"Lancet Neurol"},{"key":"1463_CR14","volume-title":"AstraZeneca","author":"A Kemp","year":"2022","unstructured":"Kemp\u00a0A (2022) Ultomiris approved in Europe for the treatment of adults with generalised myasthenia gravis. In: AstraZeneca"},{"key":"1463_CR15","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1007\/s00415-009-5120-8","volume":"256","author":"MJ Kupersmith","year":"2009","unstructured":"Kupersmith\u00a0MJ (2009) Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J\u00a0Neurol 256:1314\u20131320","journal-title":"J Neurol"},{"key":"1463_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10891-1","author":"S Lehnerer","year":"2021","unstructured":"Lehnerer\u00a0S, Jacobi\u00a0J, Schilling\u00a0R et\u00a0al (2021) Burden of disease in myasthenia gravis: taking the patient\u2019s perspective. J\u00a0Neurol. https:\/\/doi.org\/10.1007\/s00415-021-10891-1","journal-title":"J Neurol"},{"key":"1463_CR17","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","volume":"12","author":"A Marx","year":"2013","unstructured":"Marx\u00a0A, Pfister\u00a0F, Schalke\u00a0B et\u00a0al (2013) The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 12:875\u2013884","journal-title":"Autoimmun Rev"},{"key":"1463_CR18","doi-asserted-by":"publisher","first-page":"e1617","DOI":"10.1212\/WNL.0000000000010574","volume":"95","author":"M Mendoza","year":"2020","unstructured":"Mendoza\u00a0M, Tran\u00a0C, Bril\u00a0V et al (2020) Patient-acceptable symptom states in myasthenia gravis. Neurology 95:e1617\u2013e1628","journal-title":"Neurology"},{"key":"1463_CR19","doi-asserted-by":"publisher","first-page":"120084","DOI":"10.1016\/j.jns.2021.120084","volume":"432","author":"A Mirian","year":"2022","unstructured":"Mirian\u00a0A, Nicolle\u00a0MW, Edmond\u00a0P et al (2022) Comparison of fixed cell-based assay to radioimmunoprecipitation assay for acetylcholine receptor antibody detection in myasthenia gravis. J\u00a0Neurol Sci 432:120084","journal-title":"J Neurol Sci"},{"key":"1463_CR20","doi-asserted-by":"publisher","first-page":"e2368","DOI":"10.1212\/WNL.0000000000200288","volume":"98","author":"A Molimard","year":"2022","unstructured":"Molimard\u00a0A, Gitiaux\u00a0C, Barnerias\u00a0C et\u00a0al (2022) Rituximab therapy in the treatment of juvenile myasthenia gravis: the French experience. Neurology 98:e2368\u2013e2376","journal-title":"Neurology"},{"key":"1463_CR21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","volume":"60","author":"S Muppidi","year":"2019","unstructured":"Muppidi\u00a0S, Utsugisawa\u00a0K, Benatar\u00a0M et al (2019) Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 60:14\u201324","journal-title":"Muscle Nerve"},{"key":"1463_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jns.2011.03.004","volume":"305","author":"H Murai","year":"2011","unstructured":"Murai\u00a0H, Yamashita\u00a0N, Watanabe\u00a0M et al (2011) Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J\u00a0Neurol Sci 305:97\u2013102","journal-title":"J Neurol Sci"},{"key":"1463_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/14737140.2022.2052278","volume":"22","author":"Y Muto","year":"2022","unstructured":"Muto\u00a0Y, Okuma\u00a0Y (2022) Therapeutic options in thymomas and thymic carcinomas. Expert Rev Anticancer Ther 22:401\u2013413","journal-title":"Expert Rev Anticancer Ther"},{"key":"1463_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","volume":"19","author":"C Nelke","year":"2022","unstructured":"Nelke\u00a0C, Stascheit\u00a0F, Eckert\u00a0C et\u00a0al (2022) Independent risk factors for myasthenic crisis and disease exacerbation in a\u00a0retrospective cohort of myasthenia gravis patients. J\u00a0Neuroinflammation 19:89","journal-title":"J Neuroinflammation"},{"key":"1463_CR25","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.nmd.2021.09.013","volume":"31","author":"WC Ng","year":"2021","unstructured":"Ng\u00a0WC, Hartley\u00a0L (2021) Effectiveness of thymectomy in juvenile myasthenia gravis and clinical characteristics associated with better outcomes. Neuromuscul Disord 31:1113\u20131123","journal-title":"Neuromuscul Disord"},{"key":"1463_CR26","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3389\/fneur.2020.00743","volume":"11","author":"K O\u2019connell","year":"2020","unstructured":"O\u2019connell\u00a0K, Ramdas\u00a0S, Palace\u00a0J (2020) Management of juvenile myasthenia gravis. Front Neurol 11:743","journal-title":"Front Neurol"},{"key":"1463_CR27","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace\u00a0J, Newsom-Davis\u00a0J, Lecky\u00a0B (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 50:1778\u20131783","journal-title":"Neurology"},{"key":"1463_CR28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian\u00a0DC, Akilesh\u00a0S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715\u2013725","journal-title":"Nat Rev Immunol"},{"key":"1463_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1055\/a-0582-9020","volume":"45","author":"JC R\u00fcckert","year":"2018","unstructured":"R\u00fcckert\u00a0JC, Swierzy\u00a0M, Kohler\u00a0S et\u00a0al (2018) Thymektomie bei Myasthenia gravis. Akt Neurol 45:263\u2013270","journal-title":"Akt Neurol"},{"key":"1463_CR30","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","volume":"71","author":"DB Sanders","year":"2008","unstructured":"Sanders\u00a0DB, Hart\u00a0IK, Mantegazza\u00a0R et\u00a0al (2008) An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71:400\u2013406","journal-title":"Neurology"},{"key":"1463_CR31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders\u00a0DB, Wolfe\u00a0GI, Benatar\u00a0M et\u00a0al (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87:419\u2013425","journal-title":"Neurology"},{"key":"1463_CR32","doi-asserted-by":"publisher","first-page":"117957352198915","DOI":"10.1177\/1179573521989151","volume":"13","author":"M Schroeter","year":"2021","unstructured":"Schroeter\u00a0M, Berger\u00a0B, Blaes\u00a0F et al (2021) A sum score to define therapy-refractory myasthenia gravis: a German consensus. J\u00a0Cent Nerv Syst Dis 13:1179573521989151","journal-title":"J Cent Nerv Syst Dis"},{"key":"1463_CR33","first-page":"276","volume":"24","author":"AH Tilton","year":"2018","unstructured":"Tilton\u00a0AH, De Gusmao\u00a0CM (2018) Transition from pediatric to adult neurologic care. Continuum 24:276\u2013287","journal-title":"Continuum"},{"key":"1463_CR34","unstructured":"Wiendl H. MaEA (2023) Diagnostik und Therapie myasthener Syndrome, S2k-Leitlinie. Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie."},{"key":"1463_CR35","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","volume":"375","author":"GI Wolfe","year":"2016","unstructured":"Wolfe\u00a0GI, Kaminski\u00a0HJ, Aban\u00a0IB et\u00a0al (2016) Randomized trial of thymectomy in myasthenia gravis. N\u00a0Engl J Med 375:511\u2013522","journal-title":"N Engl J Med"},{"key":"1463_CR36","doi-asserted-by":"publisher","first-page":"584703","DOI":"10.3389\/fimmu.2021.584703","volume":"12","author":"E Wrona","year":"2021","unstructured":"Wrona\u00a0E, D\u0119bska-Szmich\u00a0S, Pastuszka\u00a0M et al (2021) Remission of thymoma on steroid therapy in a\u00a0patient with atypical thymoma-associated multiorgan autoimmunity: a case report and literature review. Front Immunol 12:584703","journal-title":"Front Immunol"},{"key":"1463_CR37","doi-asserted-by":"publisher","first-page":"102366","DOI":"10.1016\/j.autrev.2019.102366","volume":"18","author":"AW Zuercher","year":"2019","unstructured":"Zuercher\u00a0AW, Spirig\u00a0R, Baz Morelli\u00a0A et al (2019) Next-generation Fc receptor-targeting biologics for autoimmune diseases. Autoimmun Rev 18:102366","journal-title":"Autoimmun Rev"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-023-01463-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-023-01463-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-023-01463-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T22:58:52Z","timestamp":1702162732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-023-01463-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1463"],"URL":"https:\/\/doi.org\/10.1007\/s00115-023-01463-x","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"assertion":[{"value":"9 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Stascheit erhielt Honorare von Alexion und argenx f\u00fcr Vortr\u00e4ge und Teilnahme an wissenschaftlichen Beir\u00e4ten. A.\u00a0Della Marina ist Mitglied des \u00e4rztlichen Beirats der Deutschen Myasthenie Gesellschaft. A.\u00a0Meisel erhielt Honorare f\u00fcr Vortr\u00e4ge und Beratungen sowie (institutionelle) Forschungsf\u00f6rderung von Alexion, argenx, Axunio, Grifols, Hormosan, Janssen, Merck, Octapharma und UCB. A.\u00a0Meisel ist Vorsitzender des \u00e4rztlichen Beirats der Deutschen Myasthenie Gesellschaft (DMG).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}